AVIENCE BIOMEDICALS LTD. IPO
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.
Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.
The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas.
In addition to manufacturing, the Company also act as distributors and traders of medical equipment.
The company's manufacturing unit is situated in Noida, Uttar Pradesh.
The company offers a comprehensive range of diagnostic solutions, including:
Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test.
Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit.
Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY.
Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer.
Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM).
As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees